Questions About Cancer? 1-800-4-CANCER
  • Print
  • Facebook
  • Twitter
  • Google+
  • Pinterest

NCI Drug Dictionary


A combination therapy consisting of the prodrug tretazicar and the enzyme co-substrate caricotamide with potential antineoplastic activity. In the presence of separately and simultaneously administered caricotamide, tretazicar is converted to the short-lived cytotoxic DNA cross-linking agent dinitrobenzamide by NAD(P)H quinine oxidoreductase 2 (NQO2), resulting in the inhibition of DNA replication and the induction of apoptosis. NQO2 has been found to be elevated in certain cancers such as hepatocellular carcinoma (HCC). Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
US brand name:Prolarix
Code name:EP-0152R/CB1954
Chemical structure:1-carbamoylmethyl-3-carbamoyl-1,4-dihydropyridine/5-(aziridin-1-yl)-2,4-dinitrobenzamide